Differentiation of promyelocytic leukemia cells HL-60 induced by daidzein in vitro and in vivo.
We have screened more than one thousand synthetic and natural chemicals to explore differentiation inducers and found that daidzein has potent differentiation-inducing activity for human leukemia HL-60 cells, both in vitro and in vivo. In vitro study showed that daidzein at concentrations exceeding 10 micrograms/ml caused inhibition of HL-60 cells; and it induced differentiation of the cells into granulocytic lineage as judged by NBT reduction activity, phagocytic ability and morphological characteristics. Flow cytometry study indicated that daidzein arrested HL-60 cells in the G1 phase. The growth of HL-60 cells in the subrenal capsules of mice and in diffusion chambers implanted into the peritoneal cavities of mice was inhibited by 50 mg/kg daidzein. HL-60 cells treated with daidzein in vivo also exhibited characteristic morphological changes of matured cells. Moreover, the colony forming efficiency of HL-60 cells in diffusion chambers in mice was markedly inhibited by the administration of daidzein.
Jing
Y
Y
Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing.
Nakaya
K
K
Han
R
R
D000818:Animals; D002018:Bufanolides / Q000494:pharmacology; D002117:Calcitriol / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D004273:DNA, Neoplasm / Q000032:analysis / Q000378:metabolism; D004968:Estrogens, Non-Steroidal / Q000494:pharmacology*; D016193:G1 Phase; D006098:Granulocytes / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D007529:Isoflavones / Q000494:pharmacology*; D015473:Leukemia, Promyelocytic, Acute / Q000473:pathology*; D008419:Materia Medica / Q000494:pharmacology; D051379:Mice; D008854:Microscopy, Electron; D010587:Phagocytosis / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D002018:Bufanolides; D004273:DNA, Neoplasm; D004968:Estrogens, Non-Steroidal; D007529:Isoflavones; D008419:Materia Medica; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D014212:Tretinoin; C004742:daidzein; D007371:Interferon-gamma; D002117:Calcitriol; D013755:Tetradecanoylphorbol Acetate; C022777:bufalin